Asia-Pacific IVD Market (2025-2032)
The Asia-Pacific IVD Market was valued at $21.09 billion in 2024. This market is expected to reach $36.02 billion by 2032, from an estimated $22.44 billion in 2025, at a CAGR of 7% during the forecast period 2025-2032.
- Published
- Jan 2025
- Pages
- 230
- Format
- PDF + Excel
- Report ID
- MRHC - 1041067
- Base year
- 2024
- 2024 · BASELINE
- $21.09B
- 2032
- $36.02B
- CAGR 2025–2032
- 7%
2024 baseline · 2025–2032 forecast at 7% CAGR · hover a bar for the value
Key highlights
In 2025, the Kits & Reagents Segment is Expected to Dominate this Market
In 2025, the Molecular Diagnostics Segment is Expected to Account for the Largest Share of the Market
The Cardiology Segment Is Projected to Register the Highest CAGR During the Forecast Period
In 2025, the Laboratory Testing Segment is Expected to Dominate this Market
The Hospitals & Clinics Segment Is Projected to Register the Highest CAGR During the Forecast Period
Report summary
| Particulars | Details |
|---|---|
| Number of Pages | ~230 |
| Format | |
| Forecast Period | 2025-2032 |
| Base Year | 2024 |
| CAGR | 7% |
| Estimated Market Size (Value) | $36.02 billion by 2032 |
| Segments Covered | by Offering · Kits & Reagents · Instruments · Software & Services · by Technology · Molecular Diagnostics · Polymerase Chain Reaction (PCR) · Hybridization · Isothermal Nucleic Acid Amplification Technology · DNA Sequencing & Next-generation Sequencing · Microarrays · Mass Spectrometry · Other Molecular Diagnostic Technologies · Point of Care (PoC) Diagnostics · Lateral Flow Assays/Rapid Tests · POC Molecular Diagnostics · Other PoC Products · Immunoassay/Immunochemistry · Enzyme-linked Immunosorbent Assays (ELISA) · Radioimmunoassays · Western Blotting · Enzyme-Linked Immunospot Assays · Immunohistochemistry (IHC) · Biochemistry/Clinical Chemistry · Metabolic Panel · Electrolyte Panel · Liver Panel · Lipid Profile · Renal Profile · Thyroid Function Panel · Whole Blood Glucose Monitoring · Microbiology · Hematology · Coagulation/Hemostasis · Urinalysis · Other IVD Technologies · by Application · Infectious Diseases · COVID-19 Testing · Sexually Transmitted Diseases (STD) Testing · Healthcare-associated Infections (HAIs) · Hepatitis · HIV · Tropical Diseases · Respiratory Infections (Excluding Influenza) · Influenza · Other Infectious Diseases · Oncology · Diabetes · Cardiology · Nephrology · Autoimmune Disorders · Other Applications · by Diagnostic Approach · Lab Testing · OTC/Self-testing · Point of Care Testing · by End User · Diagnostic Laboratories · Hospitals & Clinics · Home Healthcare · Other End Users · by Country/Region · China · Japan · India · Australia · South Korea · Thailand · Singapore · Indonesia · Rest of Asia-Pacific |
| Countries Covered | Asia-Pacific (China, Japan, India, Australia, South Korea, Thailand, Singapore, Indonesia, RoAPAC) |
| Key Companies | Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), Sysmex Corporation (Japan), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Seegene Inc. (South Korea), Illumina, Inc. (U.S.), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), QuidelOrtho Corporation (U.S.), and Agilent Technologies Inc. (U.S.). |
Report overview
Segments covered: offering, technology, application, diagnostic approach. Regions: Asia-Pacific.
In vitro diagnostics (IVD) is focused on analyzing urine, blood, and other bodily fluid samples to provide diagnostic results. IVD tests help diagnose, monitor, screen, and assess susceptibility to diseases. These tests also aid in providing early and targeted treatments, reducing hospital stays, improving health outcomes, and minimizing treatment costs.
The growth of the Asia-Pacific IVD market is attributed to the rising prevalence of chronic and infectious diseases, the growing demand for point-of-care (PoC) and rapid diagnostics, rising awareness regarding early disease diagnosis, rising healthcare expenditures, and increasing funding for research activities. However, stringent technical requirements and regulatory processes for high/moderate-complexity tests and the variance in test results observed in rapid IVD tests restrain the growth of the IVD market. The increasing inclination toward personalized medicine and advancements in genomics and proteomics are expected to create growth opportunities for the players operating in this market. However, the concerns pertaining to false positive results in immunoassays and POC are a major challenge for market growth.
Report infographic
Market dynamics
3 factors across 1 forceIn February 2022,
Mylab Discovery Solutions Pvt Ltd (India) launched CoviSwift, the Point of Care (POC) testing solution.
In May 2020, the Japanese government
approved the Rapid Antigen Kit to Detect COVID-19 manufactured by Fujirebio (Japan)
Rising Prevalence of Chronic Diseases is Driving the Growth of this Market
Chronic diseases are often associated with the elderly population due to the declining bodily functions and immunity among this population segment. Aging is associated with progressive deterioration in the structure and functioning of organs. The elderly population is more prone to various chronic diseases. According to the World Bank, the share of the elderly population (aged 65 and above) in Japan is among the highest in the world and is growing at a CAGR of 1.1% (from 2016 to 2021). In 2021, the share of the elderly population in Japan was estimated at 29.8% of the country’s total population (source: World Bank).
The prevalence of chronic diseases and conditions such as cancer, diabetes, arthritis, and heart disease is on the rise in Asia-Pacific countries. In 2021, 140.9 million people were living with diabetes in China, which is expected to reach 174.4 million by 2045 (Source: IDF). Similarly, in 2021, 74.2 million people were living with diabetes in India, which is expected to reach 124.9 million by 2045 (Source: IDF). As IVD tests are widely adopted for glucose monitoring, the prevalence of diabetes drives the adoption of IVD devices.
The growth in the geriatric population and social behaviours such as tobacco and alcohol consumption, physical inactivity, and unhealthy diets are major factors driving a steady increase in the number of people suffering from chronic diseases. The growth in the elderly population and the associated increase in the burden of chronic disease is increasing the demand for IVD testing in Asia-Pacific.
Table of contents
13 chapters · 134 sections · 230 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Offering | Kits & Reagents | — |
| By Technology | Molecular Diagnostics | — |
| By Application | — | Cardiology |
| By Diagnostic Approach | Laboratory Testing | — |
| By End User | — | Hospitals & clinics |
By Offering
- The kits & reagents segment is expected to account for the largest share of the market.
- The continuous advancements in the development of reagents and kits, high adoption and recurring consumption of IVD kits, and wide availability of consumables support the largest share of the market.
- The increasing trend of self-testing and adoption of POC diagnostic testing is contributing to the largest share of this segment.
By Technology
- The molecular diagnostics segment was expected to account for the largest share of the market.
- The growing prevalence of infectious diseases is also increasing the demand for molecular diagnostics.
- For instance, In Australia, between 2020 to 2021, there were more than 324,000 hospitalizations for infectious diseases.
- The most common causes of infectious disease hospitalization were lower respiratory tract infections, including pneumonia and bronchitis.
- (Source: Australian Institute of Health and Welfare).
- Additionally, technological innovations and the advantages of molecular diagnostics tests, such as cost-effectiveness, rapid results, and high sensitivity and specificity over laboratory tests.
By Application
- The Cardiology Segment Is Projected to Register the Highest CAGR During the Forecast Period
- The cardiology segment is expected to register the highest CAGR during the forecast period.
- Cardiovascular diseases (CVD) remain the leading cause of death globally.
- IVD testing is used for biomarker detection in cardiology.
- The early-stage biomarkers of CVD can potentially save many lives and help alleviate the global burden of CVD.
- According to the American Heart Association, in 2020 highest mortality rates due to cardiovascular diseases were reported in Central Asia and Eastern Asia-Pacific.
- Thus, the high prevalence of cardiovascular diseases is expected to drive the demand for IVD testing in Asia-Pacific.
By Diagnostic Approach
- The laboratory testing segment is expected to account for the largest share of the market.
- The large market share of this segment is primarily attributed to its higher accuracy and reliability, lower costs, and availability of several IVD tests in laboratory settings.
- The laboratories usually include a quality assurance program and address pre- and post-analytical concerns, improving and maintaining the accuracy of laboratory testing.
By End User
- The hospitals & clinics segment is expected to register the highest CAGR during the forecast period.
- The highest CAGR of this segment is attributed to the increasing number of hospitalizations due to various diseases requiring diagnosis and the rise in the number of hospitals and clinics in the region, leading to growth in the utilization of diagnostic products.
Geographic analysis
Asia-Pacific
Fastest growthChina is expected to register the highest CAGR during the forecast period. The highest CAGR of this regional market is attributed to the rising prevalence of infectious & chronic diseases, the growing aging population, and the increasing adoption of self-testing. Additionally, China is one of the world's most populous countries, with a population of over 1.41 billion in 2021 (Source: World Bank). There is an increasing burden on the country's healthcare system due to the growing elderly population, high prevalence of cancer, and increasing sedentary lifestyle. According to the International Diabetes Federation (IDF), China has the highest number of people with diabetes globally. In 2021, 140.9 million people were living with diabetes in China, which is expected to reach 174.4 million by 2045 (Source: IDF). With the increasing number of chronic conditions, the demand for IVD testing is increasing in the country. China: Fastest Growing Market
Competitive landscape
- Abbott Laboratories (U.S.)
- Becton
- Dickinson and Company (U.S.)
- Sysmex Corporation · Japan
- Bio-Rad Laboratories, Inc. (U.S.)
- Danaher Corporation (U.S.)
- F. Hoffmann-La Roche Ltd. · Switzerland
- Seegene Inc. · South Korea
- Illumina, Inc. (U.S.)
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd · China
- Siemens Healthineers AG · Germany
- Thermo Fisher Scientific Inc. (U.S.)
- QuidelOrtho Corporation (U.S.)
- Agilent Technologies Inc. (U.S.)
Frequently asked questions
The Asia-Pacific IVD market is segmented based on product & solution (reagents & kits, systems, and software & services) and a wide range of technologies (immunoassay/immunochemistry, biochemistry/clinical chemistry, molecular diagnostics, microbiology, hematology, coagulation/hemostasis, urinalysis, and other technologies) offered by key companies to various end users, such as diagnostic laboratories, hospitals & clinics, home healthcare, and other end users. The Asia-Pacific IVD market studied in this report involves the value analysis of various segments and sub-segments of in-vitro diagnostics at regional and country levels.
Cite this report
Meticulous Research. (2025). Asia-Pacific IVD Market - Opportunity Analysis and Industry Forecasts (2025-2032) (Report No. MRHC - 1041067). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/asia-pacific-ivd-market-5750